MGMT Protein (His tag)

Produktnummer ABIN6700328

Hersteller Produkt- Nr.: 009-001-s47s

Produktdetails

Target: MGMT (O6-Methylguanine-DNA-Methyltransferase (MGMT))

Protein-Typ: Recombinant

Spezies: Human

Quelle: Insect cells (Sf9)

Aufreinigungstag / Konjugat: Dieses MGMT Protein ist gelabelt mit His tag.

Applikation: Western Blotting (WB)

Hersteller Produkt- Nr.: 009-001-s47s

Hersteller: Rockland

Verwendungszweck: MGMT recombinant protein-HIS Epitope

Aufreinigung: Recombinant full length human MGMT was expressed by baculovirus in Sf9 insect cells using an N-Terminal his epitope. The purity was determined to be >95% by densitometry.

Reinheit: >95%

Anwendungsinformationen

Applikationshinweise:

Western_Blot_Dilution: User Optimized

Application_Note: MGMT Protein is suitable for use in Western Blot. Expect a band approximately ~25 kDa on specific lysates or tissues. Specific conditions for reactivity should be optimized by the end user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.1 μg/μL

Buffer: MGMT Protein is stored in 50 mM sodium phosphate, pH 7.0, 300 mM NaCl, 150 mM imidazole, 0.1 mM PMSF, 0.25 mM DTT, 25 % glycerol.

Lagerung: -80 °C

Informationen zur Lagerung: Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: MGMT (O6-Methylguanine-DNA-Methyltransferase (MGMT))

Andere Bezeichnung: MGMT (MGMT Produkte)

Hintergrund:

Synonyms: Methylated-DNA--protein-cysteine methyltransferase, EC 2.1.1.63, 6-O-methylguanine-DNA methyltransferase, MGMT, O-6-methylguanine-DNA-alkyltransferase

Background: MGMT or O-6-methylguanine-DNA methyltransferase is the major mutagenic and carcinogenic lesion in DNA induced by simple alkylating mutagens. The methylation of the MGMT promoter in gliomas is a useful predictor of the responsiveness of the tumors to alkylating agents (1). The clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide (2). Methylation of the MGMT promoter in tumors is associated with longer survival in glioblastoma patients. MGMT Protein is ideal for investigators involved in Signaling Proteins, Acetyl/Methyltransferase Proteins, Apoptosis/Autophagy, Cancer, Cell Cycle, and Neurobiology research.

Pathways: DNA Reparatur, Positive Regulation of Response to DNA Damage Stimulus